Regeneron Pharmaceuticals, Inc. Lawsuit Overview
A securities class action lawsuit has emerged against REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN). This legal action is initiated for the benefit of investors who acquired Regeneron securities between specific dates within the recent year.
Class Action Details
Investors who purchased Regeneron securities during this period may seek to appoint themselves as lead plaintiff representatives for the class by a certain deadline. This opportunity allows them to play a central role in the litigation process.
Government Allegations Against Regeneron
Recently, the U.S. Department of Justice took significant steps against Regeneron under the False Claims Act. Allegations suggest that the Company failed to disclose substantial discounts given to drug distributors. This failure reportedly inflated the average sales price of Regeneron's Eylea drug, consequently increasing Medicare reimbursements unduly.
Impact of News on Stock Price
This situation led to a notable decline in Regeneron’s stock price, dropping over 3% shortly after the news broke. Share prices decreased significantly, demonstrating investors' immediate response to the unfolding allegations.
Quarterly Sales Report and Market Reaction
Further compounding challenges for Regeneron, the Company reported disappointing third-quarter sales. Earnings from Eylea did not meet market expectations, revealing that financial growth was stagnating. The stock reacted sharply, indicating market anxieties regarding the Company's future performance.
Potential Investor Participation
Investors are encouraged to explore their options for participating in this litigation. If you wish to assert your rights and potentially act as a lead plaintiff, professional legal guidance is advisable to navigate this complex process effectively.
About Berger Montague
Berger Montague, a renowned legal firm specializing in securities class action litigation, has a long-standing reputation for representing both individual and institutional investors. Their extensive experience has equipped them to handle complex securities fraud allegations, providing a crucial ally for those involved in this ongoing case.
Frequently Asked Questions
What is the basis of the lawsuit against Regeneron?
The lawsuit primarily focuses on allegations of failing to adequately disclose discounts to drug distributors, resulting in inflated sales prices for their products.
How can investors participate in the class action?
Investors can seek to become lead plaintiffs by acting before the stipulated deadline, allowing them to guide the litigation on behalf of all class members.
What impact did the lawsuit have on Regeneron's stock?
The announcement of the lawsuit and subsequent news about sales performance led to a decrease in Regeneron's stock price, reflecting investor concern over the Company’s financial health.
Who is representing the investors?
Berger Montague is advocating on behalf of investors in this case, using their extensive experience to navigate the legal complexities involved.
What are the next steps for affected investors?
Affected investors should consider reaching out to legal counsel to understand their rights and explore participation options within this class action lawsuit.
